Microba Life Sciences reported a significant increase in Q3 FY24 revenue, with $4.00m in unaudited revenue marking an 82% QoQ and 297% YoY growth, driven by strong sales in personal testing and supplements, research testing, and the successful launch of the MetaPanel Pathogen Test in Australia.
The company also highlighted progress in its therapeutic development programs, including advancing MAP 315 for Phase II in its Inflammatory Bowel Disease Program and expanding its dataset in the Immuno-Oncology Program, alongside completing 70% of Stage 2 functional screening in its Autoimmune Disease Program.
ASX Code: MAP